CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer
Wen‐Ming Chen(Guangzhou University of Chinese Medicine), Ceshi Chen(Army Medical University), Tingyue Wu(University of Science and Technology of China), Yu Rao(Soochow University), Yue Wu(Tsinghua University), Huichun Liang(Kunming Institute of Zoology), Chuanyu Yang(Kunming Institute of Zoology), Jiao Wu(Xijing Hospital), Yanjie Kong(Shenzhen Second People's Hospital), Wenlong Ren(University of Science and Technology of China)
Cited by 13
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280
Chemistries of bifunctional PROTAC degraders
|Chemical Society Reviews|2022|270